What it sells
We make cancer care at home possible.
Business model breakdown
Buyer: who owns the budget?
Health plan (payer) medical cost leaders and oncology practices/health systems.
Trigger: what makes them buy now?
High cost of in-clinic oncology infusions and clinic capacity constraints; payers want savings from day one.
Workflow: what inputs become what output?
Lotus shifts eligible oncology infusions to the home using chemo-certified nurses while drug dispensing stays with the originating clinic and integrates with existing workflows.
Economics: what it saves and how it charges
Site-of-care savings claim of $2,100 per visit for payers; payers pay nothing until savings are realised.
Distribution: how it reaches customers
Proposal-led sales to payers and providers (Get a Proposal), partner health systems.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2021 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.